Q-omics provides the consensus-scored MTND4P2 profile across patient tissues and cancer cell-line models. MTND4P2 expression is associated with patient survival in 8 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, MTND4P2 is differentially expressed in 2, with the highest sampling consensus in BLCA. Additionally, MTND4P2 RNA expression shows 6,353 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight LUAD, BLCA, and STAD as cancer lineages where MTND4P2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MTND4P2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MTND4P2 survival associations across molecular data types. MTND4P2 RNA expression shows survival associations in the most cancer types (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MTND4P2 RNA expression–survival associations across cancer types. High MTND4P2 expression shows unfavorable associations in LUAD, KIRC and PCPG, but favorable associations in HNSC, LUSC and LAML. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for MTND4P2 RNA expression.
This table summarizes MTND4P2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for MTND4P2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MTND4P2 shows higher tumor expression in BLCA and ESCA. The BLCA box plot shows higher MTND4P2 RNA expression in tumor versus normal tissue (log2 FC = +0.018, t-test p = .015).
This table shows molecular features associated with MTND4P2 in patient tissues and cancer cell lines. In patient samples, MTND4P2 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
